Nektar Therapeutics NKTR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
-
Nektar Therapeutics Reports First Quarter 2026 Financial Results
-
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR
-
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
-
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
-
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
-
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Trading Information
- Previous Close Price
- $59.21
- Day Range
- $58.88–60.75
- 52-Week Range
- $7.99–109.00
- Bid/Ask
- $59.33 / $60.18
- Shares Outstanding
- 33.79M
- Market Cap
- $2.01B
- Volume/Avg
- 534,202 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 63
- Website
- https://www.nektar.com
Valuation
|
Metric
|
NKTR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.03 |
Price/Sales | 20.80 |
Price/Cash Flow | — |
Price/Earnings
NKTR
Financial Strength
|
Metric
|
NKTR
|
|---|---|
Quick Ratio | 9.92 |
Current Ratio | 10.21 |
Interest Coverage | −4.63 |
Quick Ratio
NKTR
Profitability
|
Metric
|
NKTR
|
|---|---|
Return on Assets (Normalized) | −37.61% |
Return on Equity (Normalized) | −91.85% |
Return on Invested Capital (Normalized) | −49.55% |
Return on Assets
NKTR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dlwjmsmz | Yddfjpd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wvmqnnnd | Ndybxzt | $64B | |||
| argenx SE ADR
ARGX
| Mkbmlmf | Ycsg | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nngxvxqh | Pkcmnb | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Gscdwhbgh | Rbxpzbs | $24B | |||
| BioNTech SE ADR
BNTX
| Hzdgsmffl | Ylfh | $23B | |||
| Incyte Corp
INCY
| Zcqjwdxxd | Rkvm | $22B | |||
| Moderna Inc
MRNA
| Mldbwysm | Qtk | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vjdvjcth | Qrjw | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Mbjcngwj | Jfby | $13B |
United States